Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
DWS Health and Wellness Inst SUHIX
- NAV / 1-Day Return 42.95 / −0.37 %
- Total Assets 276.8 Mil
-
Adj. Expense Ratio
1.060%
- Expense Ratio 1.060%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1.0 Mil
- Status Open
- TTM Yield —
- Turnover 27%
USD | NAV as of Apr 16, 2024 | 1-Day Return as of Apr 16, 2024, 1:28 AM GMT+0
Morningstar’s Analysis SUHIX
Will SUHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.16 | 30.4 Mil | Healthcare |
UnitedHealth Group Inc | 8.77 | 26.2 Mil | Healthcare |
Merck & Co Inc | 4.64 | 13.9 Mil | Healthcare |
Thermo Fisher Scientific Inc | 3.74 | 11.2 Mil | Healthcare |
Johnson & Johnson | 3.67 | 11.0 Mil | Healthcare |
Boston Scientific Corp | 3.59 | 10.7 Mil | Healthcare |
Dws Central Cash Management Government Fund | 3.59 | 10.7 Mil | Cash and Equivalents |
Novo Nordisk A/S ADR | 3.51 | 10.5 Mil | Healthcare |
AbbVie Inc | 3.24 | 9.7 Mil | Healthcare |
Abbott Laboratories | 2.94 | 8.8 Mil | Healthcare |